Galectin Therapeutics Inc. — Form 10-Q Summary
Business Context and Reporting Period
Clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrosis, severe skin disease, and cancer. This unaudited quarterly filing covers the three months ended March 31, 2018, compared with the same period in 2017.
Key Financial Metrics
| Metric | Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Revenue | None significant | None significant | No commercial revenue |
| Research and development expense | $2.298 million | $3.772 million | Down 39% |
| General and administrative expense | $1.880 million | $1.174 million | Up 60% |
| Total operating expenses | $4.178 million | $4.946 million | Down 16% |
| Net loss | $4.258 million | $4.937 million | Improved by $679,000 |
| Net loss attributable to common stockholders | $4.543 million | $5.209 million | Improved by $666,000 |
| Basic and diluted loss per share | $0.12 | $0.15 | Improved |
| Cash used in operating activities | $3.516 million | $3.863 million | Improved by $347,000 |
| Net financing proceeds | $4.451 million | $2.145 million | Up $2.306 million |
| Cash and cash equivalents at period-end | $3.988 million | $13.644 million | Down $9.656 million |
Operating and net profit margins are not meaningful because the company reported no significant revenue. Stock-based compensation was $1.187 million, compared with $330,000 in Q1 2017, and materially reduced the cash loss relative to the reported net loss.
At March 31, 2018, current assets were $4.673 million and current liabilities were $2.283 million. The company had no borrowings under its $10 million related-party line of credit. The line permits borrowings through December 31, 2018, bears interest at the applicable federal rate, and is due December 31, 2019. The company issued warrants to purchase 1 million common shares in connection with the facility.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined primarily because Phase 2 clinical activities were winding down.
- General and administrative expense increased due largely to higher non-cash stock compensation and increased business development and investor-relations costs.
- Operating cash use decreased modestly, while financing proceeds increased substantially because of common-stock warrant exercises.
- Common shares outstanding increased to 37.646 million at March 31, 2018 from 35.789 million at December 31, 2017. The filing reports 37.741 million shares outstanding as of May 8, 2018.
- Warrants outstanding decreased to 11.449 million from 13.230 million at December 31, 2017 following the exercise of approximately 1.780 million warrants.
- Stockholders’ equity improved to $925,000 from a $530,000 deficit at December 31, 2017, primarily reflecting equity financing activity, although retained deficit increased to $185.711 million.
- The Nevada Supreme Court affirmed dismissal with prejudice of the state shareholder litigation on April 5, 2018. The board expects to complete its evaluation of a related demand letter.
Guidance, Outlook, Risks, and Unusual Items
Management expects continuing operating losses and has no significant revenue. Based on current forecasts, the company believes its $4.0 million of unrestricted cash, together with availability under the line of credit, is sufficient to fund currently planned operations through at least March 31, 2019. Management cautions that funding beyond available resources depends on additional financing or achieving profitable operations, neither of which is assured.
The company planned to meet with the FDA in May 2018 regarding results from the Phase 2b NASH-CX trial and a potential Phase 3 program. NASH-CX produced a non-statistically significant primary-endpoint result in the total population but reported statistically significant effects in selected subgroups, particularly patients without baseline esophageal varices. These findings require confirmation in later-stage trials and do not establish regulatory approval or commercial viability.
Key development risks include clinical-trial failure or delay, uncertain efficacy and safety, regulatory requirements, inability to obtain financing or strategic partnerships, manufacturing and commercialization challenges, intellectual-property risks, competition, stock-price volatility, and litigation-related uncertainty. The prior NASH-FX trial did not meet its primary biomarker or secondary imaging endpoints, although the compound was reported as safe and well tolerated.
Unusual or non-cash items included $1.187 million of stock-based compensation, $84,000 of non-cash interest expense related to line-of-credit warrants, $353,000 of preferred-stock dividends paid in common stock, and continued dilution from options, warrants, preferred-stock conversion rights, and equity issuances.
Investor Verification Priorities
- Verify cash burn, unrestricted cash, and the stated runway through March 31, 2019 against current financing availability and clinical spending plans.
- Review the terms, related-party nature, availability, and potential dilution associated with the $10 million line of credit and its warrants.
- Assess NASH-CX subgroup results, statistical significance, clinical relevance, and the FDA’s response before assigning value to a potential Phase 3 program.
- Quantify fully diluted shares, including 11.449 million warrants, 5.615 million options, and 4.312 million shares issuable upon preferred-stock conversion.
- Monitor the company’s ability to raise additional capital given its history of losses, lack of significant revenue, and substantial retained deficit.
- Confirm the resolution and any remaining exposure associated with the shareholder demand letter and related litigation.